請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66363完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李心予(Hsinyu Lee) | |
| dc.contributor.author | Tsui-Hwa Lin | en |
| dc.contributor.author | 林翠華 | zh_TW |
| dc.date.accessioned | 2021-06-17T00:32:04Z | - |
| dc.date.available | 2013-03-19 | |
| dc.date.copyright | 2012-03-19 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2012-02-10 | |
| dc.identifier.citation | 1. Chen PC, Tsai MH, Yip SK, Jou YC, Ng CF, Chen Y, Wang X, Huang W, Tung CL, Chen GC et al: Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med Genomics 2011, 4:45.
2. Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M et al: Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Science 2004, 95(12):955-961. 3. Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kotani K, Yoshimura K, Terai A, Arai Y, Yoshiki T: Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clinical Chemistry 2004, 50(5):857-866. 4. Lu YC, Chen CN, Wang B, Hsu WM, Chen ST, Chang KJ, Chang CC, Lee H: Changes in tumor growth and metastatic capacities of J82 human bladder cancer cells suppressed by down-regulation of calreticulin expression. Am J Pathol 2011, 179(3):1425-1433. 5. Bedard K, Szabo E, Michalak M, Opas M: Cellular functions of endoplasmic reticulum chaperones calreticulin, calnexin, and ERp57. Int Rev Cytol 2005, 245:91-121. 6. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M: Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochemical Journal 2009, 417:651-666. 7. Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM, Michalak M, Murphy-Ullrich JE: Calreticulin: non-endoplasmic reticulum functions in physiology and disease. Faseb Journal 2010, 24(3):665-683. 8. Mesaeli N NK, Zvaritch E, Dickie P, Dziak E, Krause KH, Opas M,, MacLennan DH MM: Calreticulin is essential for cardiac development. J Cell Biol 1999, 8;144(5):857-868. 9. Dai E, Stewart M, Ritchie B, Mesaeli N, Raha S, Kolodziejczyk D, Hobman ML, Liu LY, Etches W, Nation N et al: Calreticulin, a potential vascular regulatory protein, reduces intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 1997, 17(11):2359-2368. 21 10. Michalak M, Lynch J, Groenendyk J, Guo L, Robert Parker JM, Opas M: Calreticulin in cardiac development and pathology. Biochim Biophys Acta 2002, 1600(1-2):32-37. 11. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G: Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008, 20(5):504-511. 12. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13(1):54-61. 13. Gardai SJ MK, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE,, Bratton DL OP, Michalak M, Henson PM: Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 21(23):321-334. 14. Coppolino MG DS: Bi-directional signal transduction by integrin receptors.. Int J Biochem Cell Biol 2000 32(2):171-188. 15. Papp S, Fadel MP, Michalak M, Opas M: Analysis of the suitability of calreticulin inducible HEK cells for adhesion studies: microscopical and biochemical comparisons. Molecular and Cellular Biochemistry 2008, 307(1-2):237-248. 16. Coppolino MG, Dedhar S: Ligand-specific, transient interaction between integrins and calreticulin during cell adhesion to extracellular matrix proteins is dependent upon phosphorylation dephosphorylation events. Biochemical Journal 1999, 340:41-50. 17. Nanney LB, Woodrell CD, Greives MR, Cardwell NL, Pollins AC, Bancroft TA, Chesser A, Michalak M, Rahman M, Siebert JW et al: Calreticulin enhances porcine wound repair by diverse biological effects. American Journal of Pathology 2008, 173(3):610-630. 18. Coppolino MG, Woodside MJ, Demaurex N, Grinstein S, StArnaud R, Dedhar S: Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 1997, 386(6627):843-847. 19. Goicoechea S OA, Pallero MA, Eggleton P, Murphy-Ullrich JE.: Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. . J Biol Chem 2000, 17(275):36358-36368. 20. Goicoechea S PM, Eggleton P, Michalak M, Murphy-Ullrich JE.: The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin.. J Biol Chem 2002, 4(277):37219-37228. 21. Pallero MA EC, Chen J, Mosher DF, Murphy-Ullrich JE.: Thrombospondin 1 22 ding to calreticulin-LRP1 signals resistance to anoikis. FASEB J 2008, 22(11):3968-3979. 22. Kwon MS, Park CS, Choi K, Ahnn J, Kim JI, Eom SH, Kaufman SJ, Song WK: Calreticulin couples calcium release and calcium influx in integrin-mediated calcium signaling. Mol Biol Cell 2000, 11(4):1433-1443. 23. Coppolino M L-HC, Dedhar S, Wilkins J.: Inducible interaction of integrin alpha 2 beta 1 with calreticulin. Dependence on the activation state of the integrin. J Biol Chem 1995 Sep 29;270(39):23132-8 Coppolino M, Leung-Hagesteijn C, Dedhar S, Wilkins J 1995, 29(270):23132-23138. 24. Tran H PR, Tran SD, Hampton B, Burgess WH, Yamada KM.: Integrin clustering induces kinectin accumulation. J Cell Sci 2002, 15(115):2031-2040. 25. Kreis S, Schonfeld HJ, Melchior C, Steiner B, Kieffer N: The intermediate filament protein vimentin binds specifically to a recombinant integrin alpha 2/beta 1 cytoplasmic tail complex and co-localizes with native alpha 2/beta 1 in endothelial cell focal adhesions. Experimental Cell Research 2005, 305(1):110-121. 26. Elton CM, Smethurst PA, Eggleton P, Farndale RW: Physical and functional interaction between cell-surface calreticulin and the collagen receptors integrin alpha 2 beta 1 and glycoprotein VI in human platelets. Thrombosis and Haemostasis 2002, 88(4):648-654. 27. Gold LI, Rahman M, Blechman KM, Greives MR, Churgin S, Michaels J, Callaghan MJ, Cardwell NL, Pollins AC, Michalak M et al: Overview of the role for calreticulin in the enhancement of wound healing through multiple biological effects. Journal of Investigative Dermatology Symposium Proceedings 2006, 11(1):57-65. 28. Lange-Asschenfeldt B, Velasco P, Streit M, Hawighorst T, Pike SE, Tosato G, Detmar M: The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. Journal of Investigative Dermatology 2001, 117(5):1036-1041. 29. Lee H, Goetzl EJ, An S: Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am J Physiol Cell Physiol 2000, 278(3):C612-618. 30. Streblow DN, Dumortier J, Moses AV, Orloff SL, Nelson JA: Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol 2008, 325:397-415. 31. Xu KP, Yin J, Yu FS: Lysophosphatidic acid promoting corneal epithelial 23 wound healing by transactivation of epidermal growth factor receptor. Invest Ophthalmol Vis Sci 2007, 48(2):636-643. 32. Cheresh DA: Structural and biologic properties of integrin-mediated cell adhesion. Clin Lab Med 1992, 12(2):217-236. 33. Arnaout MA, Goodman SL, Xiong JP: Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol 2007, 19(5):495-507. 34. Hakomori S: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996, 56(23):5309-5318. 35. Link-Lenczowski P, Litynska A: Glycans in melanoma screening. Part 2. Towards the understanding of integrin N-glycosylation in melanoma. Biochem Soc Trans 2011, 39(1):374-377. 36. Dennis JW, Granovsky M, Warren CE: Protein glycosylation in development and disease. Bioessays 1999, 21(5):412-421. 37. Mas E, Pasqualini E, Caillol N, El Battari A, Crotte C, Lombardo D, Sadoulet MO: Fucosyltransferase activities in human pancreatic tissue: comparative study between cancer tissues and established tumoral cell lines. Glycobiology 1998, 8(6):605-613. 38. Barreau C, Paillard L, Osborne HB: AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res 2005, 33(22):7138-7150. 39. Khabar KS: Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. Cell Mol Life Sci 2010, 67(17):2937-2955. 40. Meisner NC HJ, Uhl V, Aszódi A, Jaritz M, Auer M.: mRNA openers and closers: modulating AU-rich element-controlled mRNA stability by a molecular switch in mRNA secondary structure. Chembiochem 2004 5(10):1432-1447. 41. Brennan CM, Steitz JA: HuR and mRNA stability. Cell Mol Life Sci 2001, 58(2):266-277. 42. Bevilacqua A, Ceriani MC, Capaccioli S, Nicolin A: Post-transcriptional regulation of gene expression by degradation of messenger RNAs. J Cell Physiol 2003, 195(3):356-372. 43. Bakheet T, Frevel M, Williams BR, Greer W, Khabar KS: ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res 2001, 29(1):246-254. 44. Bakheet T, Williams BR, Khabar KS: ARED 2.0: an update of AU-rich element mRNA database. Nucleic Acids Res 2003, 31(1):421-423. 45. Zhang Z, Sun P, Liu J, Fu L, Yan J, Liu Y, Yu L, Wang X, Yan Q: Suppression of 24 FUT1/FUT4 expression by siRNA inhibits tumor growth. Biochim Biophys Acta 2008, 1783(2):287-296. 46. Becker DJ, Lowe JB: Fucose: biosynthesis and biological function in mammals. Glycobiology 2003, 13(7):41R-53R. 47. Yan L, Lin B, Gao L, Gao S, Liu C, Wang C, Wang Y, Zhang S, Iwamori M: Lewis (y) Antigen Overexpression Increases the Expression of MMP-2 and MMP-9 and Invasion of Human Ovarian Cancer Cells. Int J Mol Sci 2010, 11(11):4441-4452. 48. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92(8):827-839. 49. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE: Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 1990, 50(7):2183-2190. 50. Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG: High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res 2005, 7(5):R780-787. 51. Kitamura K, Stockert E, Garin-Chesa P, Welt S, Lloyd KO, Armour KL, Wallace TP, Harris WJ, Carr FJ, Old LJ: Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants. Proc Natl Acad Sci U S A 1994, 91(26):12957-12961. 52. Totary-Jain H, Naveh-Many T, Riahi Y, Kaiser N, Eckel J, Sasson S: Calreticulin destabilizes glucose transporter-1 mRNA in vascular endothelial and smooth muscle cells under high-glucose conditions. Circulation Research 2005, 97(10):1001-1008. 53. Nickenig G MF, Müller C, Berger A, Vogel T, Sachinidis A, Vetter H, Böhm M.. Destabilization of AT1 receptor mRNA by calreticulin. . Circ Res 2002, 90:53–58. 54. Yokoyama M, Hirata K: New function of calreticulin: calreticulin-dependent mRNA destabilization. Circulation Research 2005, 97(10):961-963. 55. Marc Coppolino CL-H, Shoukat Dedhar, and John Wilkins: Inducible Interaction of Integrin a2b1 with Calreticulin. THE JOURNAL OF BIOLOGICAL CHEMISTRY 1995, 270(39): 23132–23138. 56. Isaji T, Sato Y, Fukuda T, Gu J: N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1. J 25 Biol Chem 2009, 284(18):12207-12216. 57. Janik ME, Litynska A, Vereecken P: Cell migration-the role of integrin glycosylation. Biochimica Et Biophysica Acta 2010, 1800(6):545-555. 58. Mejias-Luque R, Lopez-Ferrer A, Garrido M, Fabra A, de Bolos C: Changes in the invasive and metastatic capacities of HT-29/M3 cells induced by the expression of fucosyltransferase 1. Cancer Science 2007, 98(7):1000-1005. 59. Moehler TM, Sauer S, Witzel M, Andrulis M, Garcia-Vallejo JJ, Grobholz R, Willhauck-Fleckenstein M, Greiner A, Goldschmidt H, Schwartz-Albiez R: Involvement of alpha 1-2-fucosyltransferase I (FUT1) and surface-expressed Lewis(y) (CD174) in first endothelial cell-cell contacts during angiogenesis. J Cell Physiol 2008, 215(1):27-36. 60. Aubert M, Panicot L, Crotte C, Gibier P, Lombardo D, Sadoulet MO, Mas E: Restoration of alpha(1,2) fucosyltransferase activity decreases adhesive and metastatic properties of human pancreatic cancer cells. Cancer Research 2000, 60(5):1449-1456. 61. Koda Y, Soejima M, Kimura H: Structure and expression of H-type GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase gene (FUT1). Two transcription start sites and alternative splicing generate several forms of FUT1 mRNA. J Biol Chem 1997, 272(11):7501-7505. 62. Zhang Z, Sun P, Liu J, Fu L, Yan J, Liu Y, Yu L, Wang X, Yan Q: Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth. Biochimica Et Biophysica Acta 2008, 1783(2):287-296. 63. Fukushima K, Satoh T, Baba S, Yamashita K: alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology 2010, 20(4):452-460. 64. Rojiani MV, Finlay BB, Gray V, Dedhar S: In vitro interaction of a polypeptide homologous to human Ro/SS-A antigen (calreticulin) with a highly conserved amino acid sequence in the cytoplasmic domain of integrin alpha subunits. Biochemistry 1991, 30(41):9859-9866. 65. Michalak M, Milner RE, Burns K, Opas M: Calreticulin. Biochem J 1992, 285 ( Pt 3):681-692. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66363 | - |
| dc.description.abstract | Calreticulin (CRT) localizes to intracellular, cell surface and extracellular compartments and regulates a variety of diverse and important biological processes. CRT ensures proper folding of proteins and glycoproteins regulating homeostatic control of cytosolic and ER calcium levels. CRT is necessary for cell adhesion, migration and phagocytosis of apoptotic cells.
CRT can be detected in urine of bladder cancer patients as a cancer marker. Higher concentration of urinary CRT tends to increase pathologic stages of tumor. Down-regulation of CRT suppresses tumor growth and metastatic capacities in human bladder cancer. Glycosylation of integrin modulates the binding strength of integrin and extracellular matrix (ECM) binding. Fucosyltransferase 1 (FUT1) expression and fucosylation of β1 integrin, catalyzed by FUT1, were down-regulated when CRT in human bladder cancer cells was knocked down (data unpublished). Suppression of FUT1 expression and fucosylation of β1 integrin may lead to modulation of tumor cell attachment and tumor malignances. Real-time PCR and mRNA degradation assays have indicated that half-life of FUT1 mRNA is much shorter in bladder cancer cells transfected with CRT-RNAi than in the control cells. These data implicated that the suppression of FUT1 expression might due to instability of FUT1 mRNA. In this IV study, we built EGFP-FUT1 3’UTR constructions with wild type adenylate-uridin rich element (ARE), mutated ARE and deleted ARE respectively. By transfecting each of these three constructions in J82 bladder cancer cells, we found that CRT plays a crucial role in modulating FUT1 mRNA stability through interacting with ARE in 3’UTR of FUT1 mRNA. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T00:32:04Z (GMT). No. of bitstreams: 1 ntu-100-R98b41011-1.pdf: 1078613 bytes, checksum: 3483caa696eacfab99e17fc30657c391 (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | Contents
致謝............................................................................................................................... I 摘要............................................................................................................................... II Abstract ........................................................................................................................ III Introduction .................................................................................................................... 1 Bladder cancer ....................................................................................................... 1 Structure and physiological functions of CRT ....................................................... 2 Correlation between CRT and integrins ................................................................ 3 Structure and physiological functions of integrin .................................................. 4 The control of mRNA stability .............................................................................. 5 Cell line and cell culture ........................................................................................ 8 Construction of EGFP-FUT1 3’UTR expression systems ..................................... 8 Flow cytometric analyses ..................................................................................... 11 Delta vision analyses............................................................................................ 12 Statistic analyses .................................................................................................. 12 Plasmid constructions and transfection ................................................................ 13 Flow cytometric analyses ..................................................................................... 13 Delta vision analyses............................................................................................ 14 Reference ...................................................................................................................... 20 Tables ........................................................................................................................... 26 Figures ......................................................................................................................... 31 | |
| dc.language.iso | en | |
| dc.subject | alpha(1 | zh_TW |
| dc.subject | 2)-岩藻醣轉移酶 | zh_TW |
| dc.subject | 鈣網蛋白 | zh_TW |
| dc.subject | 多腺嘌呤-尿嘧啶序列 | zh_TW |
| dc.subject | Calreticulin | en |
| dc.subject | A-U rich Element | en |
| dc.subject | Fucosyltransferase 1 | en |
| dc.title | "鈣網蛋白經由多腺嘌呤-尿嘧啶序列調控膀胱癌細胞J82之alpha(1,2)-岩藻醣轉移酶表達" | zh_TW |
| dc.title | Calreticulin Regulates Fucosyltransferase 1 Expression in Bladder Cancer Cell through A-U rich Element of 3’UTR | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 100-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳俊宏,張正琪,朱家瑩 | |
| dc.subject.keyword | 鈣網蛋白,多腺嘌呤-尿嘧啶序列,alpha(1,2)-岩藻醣轉移酶, | zh_TW |
| dc.subject.keyword | Calreticulin,A-U rich Element,Fucosyltransferase 1, | en |
| dc.relation.page | 40 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2012-02-10 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 動物學研究所 | zh_TW |
| 顯示於系所單位： | 動物學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 未授權公開取用 | 1.05 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。